LUNDBECK A Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

· Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD) · Urinary free cortisol (UFC) normalization is a clinically relevant measure in CD, where chronic cortisol excess is a key driver of morbidity, mortality and quality-of-life burden · Preliminary Phase II Part A data showed UFC normalization in most evaluable adults with CD who completed individualized intravenous dose titration with asedebart[1] Valby, Denmark, Sunday 14 June 2026 – H. Lundbeck A/S...

Upcoming presentations at ENDO 2026 highlight Lundbeck's Focused Innovator strategy and continued expansion into rare neuroendocrine diseases with high unmet medical needs The scientific program showcases Lundbeck's investigational neurohormonal and neuroimmunological targeted therapeutic......

Ulf Wiinberg in den Verwaltungsrat berufen William „Bill“ MacKenzie zum Senior Vice President – Finance ernannt CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics gab heute die Ernennung von Ulf Wiinberg in den Verwaltungsrat sowie von William „Bill“ MacKenzie zum Senior Vice President – Finance bekannt. Herr Wiinberg ist eine erfahrene Führungskraft in den Bereichen Biotechnologie, Pharmazie und Gesundheitswesen mit einer langjährigen internationalen Karriere. Als Mitglied des Verwaltungsrats wird er mit strategischer Beratung und Branchenexpertise dazu beitragen, die Entwicklungs- und Vermarktungsstrategie des Unternehmens zu unterstützen. Zu Herrn Wiinbergs beruflichen Stationen zählt die Tätigkeit als CEO der X-Vax Technology, Inc. von 2017 bis 2024; davor war er von 2008 bis 2014 CEO von Lundbeck. Von 2002 bis 2008 war er Mitglied des Führungsgremiums von Wyeth; in dieser Zeit war er von 2002 bis 2005 weltweiter Präsident von Wyeth Consumer Healthcare und bis 2008, als Wye...

Ulf Wiinberg appointed to Board of Directors William “Bill” MacKenzie hired as Senior Vice President – Finance CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics today announced the appointment of Ulf Wiinberg to its Board of Directors and William “Bill” MacKenzie as Senior Vice President – Finance. Mr. Wiinberg is a seasoned biotechnology, pharmaceutical and healthcare industries executive with an extensive global career. As a member of the Board of Directors, he will contribute strategic guidance and industry expertise to support the Company's development and commercialization strategy. Mr. Wiinberg's experience includes serving as CEO of X-Vax Technology, Inc. from 2017 until 2024 and prior to that, he was CEO of Lundbeck from 2008 until 2014. From 2002 to 2008, he was a member of Wyeth's Management Committee and during this time, he was Worldwide President of Wyeth Consumer Healthcare from 2002 to 2005, and President of Europe/Middle East/Africa until 2008, when Wyeth was acqui...

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly migraine days versus placebo over Weeks 1–12 in patients with one to four prior preventive treatment failures......

New 12-month data from the INFUSE study show patient-reported outcomes related to multiple migraine-related cognitive symptoms in participants who failed at least one prior calcitonin gene-related peptide (CGRP)-targeted therapy1 Six-month data from the INFUSE study was recently published in Cephalalgia Reports, an official journal of the International Headache Society New PROCEED phase 2b route of administration and dose-finding trial results of bocunebart (Lu AG09222; anti-PACAP mAb) being investigated in migraine prevention2 DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck US, the US subsidiaries of H. Lundbeck A/S., today announced the presentation of new VYEPTI® (eptinezumab-jjmr) data at the American Headache Society's (AHS) 68th Annual Scientific Meeting, taking place June 4-7, 2026, in Orlando, Florida. The presentations will share findings from the INFUSE, DELIVER, SUNSET, and RESOLUTION trials, featuring real-world data and phase 3 clinical trial post-hoc analyses of VYEPTI and patient-reported outc...

Collaboration's initial focus will focus on two antibody programs targeting CNS diseases VALBY, Denmark & AMSTERDAM, 03 June 2026 – H. Lundbeck A/S (Lundbeck), a global biopharmaceutical company focused exclusively on brain health, and Cradle, a leading AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. It is estimated that more than half of the world's population is impacted by brain disorders, and the effects are felt throughout society. Speeding up innovation time to...

Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adults Authorization supported by the Phase 3 SUNRISE trial conducted in a predominantly......

Congenital adrenal hyperplasia (CAH) and Cushing's disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain1,2 Current treatments are limited by suboptimal disease control and treatment-related complications3,4 Asedebart (Lu AG13909)......

Key highlights Lundbeck's total revenue grew by +21% CER[1] (+14% DKK) to DKK 7,125 million in the first quarter of 2026, with all regions contributing double-digit growth. As planned, Lundbeck made progress sharpening its commercial model by establishing 27 partner markets[2]. Adjusting for the planned one-time DKK 470 million inventory build in these markets, total revenue grew by +13% CER · United States: DKK 3,482 million (+20% CER; +6% DKK) · Europe: DKK 1,799 million (+24% CER; +25% DKK) · International Operations: DKK 1,616 million (+13% CER; +6% DKK) · Adjusting...

H. Lundbeck A/S (Lundbeck) raises financial guidance for the full-year revenue and adjusted EBITDA growth at constant exchange rates (CER). Lundbeck has increased its 2026 revenue outlook, primarily reflecting stronger expected full-year volumes for Vyepti[ ][®] in the U.S., anticipated delay of Abilify Maintena[®] generic entry in key markets outside US, and a stronger-than-expected start in the newly established partner markets. Lundbeck now expects R&D investments of approximately DKK 5.6 - 5.9 billion. The updated guidance at CER is outlined below: Financial guidance for 2026...

• The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure VALBY, Denmark, April 19, 2026 /PRNewswire/ -- H. Lundbeck......

Seven abstracts represent data across migraine, childhood-onset epilepsy and multiple system atrophy (MSA), highlighting Lundbeck's biology-driven approach to developing treatments for serious brain diseases Oral presentation of new Phase 1 safety and tolerability data for bocunebart (Lu......

Appointments support Harmony's next phase of growth and long‑term value creationPLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight across the business during a period of continued growth and operational evolution. He brings more than three decades of experience building and leading biotechnology organizations. Most recently, Mr. Anastasiou served as Chief Executive Officer of Capsida Biotherapeutics and previously held multiple leadership roles at Lundbeck, including President of U.S. and Canadian operations and U.S. Chief Commercial Officer for its psychiatry and ...

H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted and the annual report was approved at the annual general meeting. The proposal to distribute a dividend of 36% of the net profit and 30% of net profit adjusted for the impairment loss of the planned divestment of a non-core production site in Italy for the accounting year 2025, corresponding to DKK 1.15 per share, or a total dividend of DKK 1,145 million, was adopted. The Remuneration Report for 2025 was approved in the advisory vote. Dorothea Wenzel, Lene Skole-Sørensen, Lars Erik...

Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson's disease, to be presented at the 2026 AD/PD™ Conference Data evaluated safety, tolerability, pharmacokinetics and early clinical signals of Lu AF28996 Five accepted presentations reflect......

H. Lundbeck A/S will focus its capital investments on the US and China rather than Europe as the region faces growing pressure to incentivize innovation, according to the Danish drugmaker's chief executive officer....

VALBY, Denmark, March 10, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced the appointment of Markus Kede as Senior Vice President, Chief AI Officer. He will join the Executive Leadership Team and report to President and CEO, Charl van Zyl. The appointment marks an......

· MASCOT is a first-of-its-kind, Phase 3 trial supporting the development of amlenetug, an investigational therapy for people living with multiple system atrophy (MSA), a rare and fatal neurodegenerative disorder[1] · Amlenetug is a novel monoclonal antibody that demonstrated promising results in a Phase 2 trial, suggesting potential to slow disease progression in MSA · Early completion of randomization underscores the significant unmet need in MSA, strong collaboration with patient and investigator communities, and Lundbeck's robust research and development capabilities · Headline...